← Back to TIL
First Gear / July 22, 2026

Claims Age Quickly

Aggregation

World

1 critical / 2 happenings

Aggregation

Tech

3 critical / 2 happenings

Ideation

Ideation

Idea 1 Claim Freshness Ledger

Sell pharma and regulated-health marketers a claim engine that turns every public comparison into a living evidence object. It watches approvals, trial data, label changes, competitor claims, local ad variants, influencer scripts, and answer-engine snippets, then flags exactly when a claim that was legal yesterday becomes misleading today.

Source Signals

Why Now: Health marketing is moving toward always-on DTC campaigns, social variants, and AI-assisted localization while evidence and regulatory positions change weekly. The old MLR workflow assumes a finite asset; the new risk is a claim graph that drifts after launch.

First Wedge: Start with GLP-1 and metabolic-drug comparative advertising in the US: ingest labels, trial publications, FDA approvals, competitor ads, and the brand's own campaign inventory; output a red/yellow/green evidence packet for each claim and the exact edit needed.

Commercial Model: Legal, regulatory, and brand teams pay per brand or therapeutic area, with premium pricing for monitored competitor-claim intelligence. The budget exists because injunctions, corrective advertising, and pulled campaigns are expensive and urgent.

Defensibility: The compounding asset is a mapped library of claims, endpoints, disclaimers, jurisdictions, substantiation packets, and regulator outcomes. Incumbent MLR tools can add AI review, but they do not naturally own the cross-brand evidence-change graph or external campaign monitoring.

Technical Risk: The hard part is not summarizing ads; it is representing clinical comparability, approved dosing, endpoint differences, implied claims, and jurisdictional rules in a way lawyers trust. False positives will kill adoption if reviewers feel the system is another noisy checklist.

Market Expansion: After GLP-1, expand to dermatology, fertility, supplements, medtech, payer-facing benefit claims, and eventually any regulated product where evidence changes faster than campaign review cycles.

Self-Critique: This could collapse into services-heavy compliance work. The wedge only clears the bar if the product produces defensible evidence packets and external drift alerts faster than a legal team or agency can do manually.

Next Experiment: In two weeks, build a GLP-1 claim diff on 25 public Zepbound/Wegovy ads and labels, ask three pharma regulatory reviewers to mark blind outputs, and measure whether the system catches material drift they would escalate.

Idea 2 Proof Packs for Software Factories

Sell engineering leaders a proof-pack layer for agent-built code: every agent change must ship with a small, machine-checkable dossier showing intent, affected contracts, authoring model, independent review model, tests, policy gates, and any formal proof or runtime invariant the change touched. The product is not another coding agent; it is the receipt that makes agent labor acceptable in serious systems.

Source Signals

Why Now: Code generation is getting cheap enough that the scarce resource becomes review capacity and trust. Agent-native workspaces and software factories increase change volume, while formal verification and cross-model review are just becoming practical enough to attach proof to narrow classes of changes.

First Wedge: Start with SOC 2/HIPAA-adjacent B2B SaaS teams using coding agents on backend services. For each PR, generate a proof pack that maps changed routes, schemas, auth checks, migrations, tests, reviewer model, and approval rationale into an auditor-readable record.

Commercial Model: VP Engineering, Security, or Compliance pays per repo or per agent-seat bundle. The budget comes from reducing review bottlenecks, preserving audit readiness, and letting agent-generated code touch more valuable parts of the system.

Defensibility: The data moat is a corpus of agent-authored change dossiers tied to post-merge incidents, audit outcomes, and reviewer overrides. That teaches the system which proof artifacts actually predict survivable deployments in each codebase.

Technical Risk: The hard part is building static and runtime contract extraction that is specific enough to catch missing behavior without drowning teams in generic warnings. Formal proof is only useful for narrow surfaces at first, so the product must degrade gracefully to evidence packs where proof is unavailable.

Market Expansion: Move from web backends into infra-as-code, fintech ledger changes, medical workflow software, autonomous remediation, and eventually insurer-required warranties for agent-built software.

Self-Critique: AI code review, governance, and audit logs are already crowded. The wedge must stay narrower: proof packs tied to deployability and audit evidence, not a general agent-security dashboard.

Next Experiment: Instrument five agent-heavy repos for two weeks, generate proof packs on every PR, and ask maintainers which packs would have changed merge or rollback decisions. The success metric is fewer human review minutes on low-risk changes without missed high-severity defects.